Mog1p Inhibitors
Chemical inhibitors of Mog1p operate by interfering with cellular processes that are essential for the functional performance of the protein. Alisertib and MLN8237, both Aurora kinase A inhibitors, lead to the disruption of mitotic spindle formation, a process to which Mog1p is indirectly connected through its role in nucleocytoplasmic transport. Similarly, BI-2536, a Polo-like kinase 1 (Plk1) inhibitor, induces mitotic arrest, thereby hindering the cellular context in which Mog1p operates, leading to its functional inhibition. The Aurora kinase inhibitor ZM447439 and the Aurora kinases inhibitor VX-680 (Tozasertib) both obstruct chromosome alignment and segregation during mitosis, processes that require the functional involvement of Mog1p. Disruption of these processes by these inhibitors therefore results in the functional inhibition of Mog1p.
Further, CDK inhibitors such as Purvalanol A, Roscovitine, and Dinaciclib, prevent cell cycle progression at various phases, which impacts the nucleocytoplasmic transport necessary for cell cycle events where Mog1p is involved. As Mog1p assists in cell cycle-related events, the arrest caused by these inhibitors leads to its indirect inhibition. Lestaurtinib, a Janus kinase 2 (JAK2) inhibitor, disrupts JAK2-dependent cell cycle control, a pathway that Mog1p is involved in, resulting in its functional inhibition. Palbociclib (PD 0332991), a CDK4/6 inhibitor, interrupts the G1-S phase transition, which is fundamental for the progression of cell cycle events that rely on nucleocytoplasmic transport, leading to the indirect inhibition of Mog1p. Lastly, SNS-032, which inhibits CDK2, CDK7, and CDK9, affects transcription and cell cycle progression, thereby disrupting processes in which Mog1p is critically involved, and as such, results in the functional inhibition of Mog1p.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora kinase A inhibitor. Mog1p is involved in nucleocytoplasmic transport, which is essential for mitotic processes. Aurora kinase A plays a crucial role in mitosis. Inhibition of Aurora kinase A by Alisertib can disrupt the mitotic spindle formation, which is a process where Mog1p is indirectly involved, leading to its functional inhibition. | ||||||
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $151.00 $525.00 | 8 | |
BI-2536 is a Polo-like kinase 1 (Plk1) inhibitor. Plk1 is pivotal for mitotic progression, which is interconnected with nucleocytoplasmic transport where Mog1p functions. Inhibition of Plk1 by BI-2536 can lead to mitotic arrest, indirectly inhibiting Mog1p by disrupting the cellular context in which it operates. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM447439 is an Aurora kinase inhibitor. By inhibiting Aurora kinases, this compound can interfere with chromosome alignment and segregation during mitosis. Since Mog1p has a role in the cell cycle, the disruption of mitosis by ZM447439 would indirectly inhibit the functional role of Mog1p. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
VX-680, also known as Tozasertib, is an inhibitor of Aurora kinases. As Aurora kinases are critical for proper chromosomal segregation and spindle assembly, their inhibition by VX-680 can disrupt processes in which Mog1p is functionally involved, leading to its inhibition. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is a cyclin-dependent kinase (CDK) inhibitor. CDKs are essential for cell cycle regulation, and Mog1p is implicated in cell cycle-related events. By inhibiting CDKs, Purvalanol A can prevent the cell cycle progression, which indirectly inhibits Mog1p by halting the cellular processes it supports. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is another CDK inhibitor. It can halt cell cycle progression at various phases, impacting the nucleocytoplasmic transport necessary for cell cycle events where Mog1p is involved, thus indirectly inhibiting Mog1p. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a broad CDK inhibitor. By inhibiting CDKs, it disrupts cell cycle progression. Since Mog1p plays a role in nucleocytoplasmic transport that is tied to cell cycle phases, Dinaciclib can indirectly inhibit Mog1p by arresting the cell cycle. | ||||||
AZD1152-HQPA | 722544-51-6 | sc-265334 | 10 mg | $375.00 | ||
AZD1152-HQPA is a selective Aurora B kinase inhibitor. Inhibition of Aurora B kinase can lead to cytokinesis failure, which is a process that Mog1p indirectly supports through its role in nucleocytoplasmic transport, thus resulting in Mog1p inhibition. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $275.00 $326.00 $612.00 | 3 | |
Lestaurtinib, known also as CEP-701, is a Janus kinase 2 (JAK2) inhibitor. JAK2 is involved in various signaling pathways that include cell cycle regulation. Mog1p, involved in nucleocytoplasmic transport, can be indirectly inhibited by Lestaurtinib through disruption of JAK2-dependent cell cycle control. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor. Since CDK4/6 are crucial for G1-S phase transition, their inhibition by Palbociclib can interrupt the cell cycle, leading to an indirect inhibition of Mog1p by preventing the progression of cell cycle events that rely on nucleocytoplasmic transport. | ||||||